|
業務類別
|
Biotechnology |
|
業務概覽
|
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform. |
| 公司地址
| 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ, USA, 07701 |
| 電話號碼
| +1 732 889-3111 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cantonstrategic.com |
| 員工數量
| 12 |
| Mr. Mark Paul Wendland |
Chief Executive Officer and Chairman of the Board |
美元 83.33K |
06/02/2026 |
| Mr. Sireesh Appajosyula |
Director and Chief Operating Officer |
美元 376.26K |
31/03/2026 |
| Ms. Angela Dominy Radkowski |
Chief Operating Officer |
-- |
06/02/2026 |
| Mr. Mark Christopher Toomey |
President |
美元 83.33K |
31/03/2026 |
| Mr. Jacob Asbury |
Chief Financial Officer |
美元 22.50K |
31/03/2026 |
|
|
| Mr. Clay Kahler |
Independent Director |
31/03/2026 |
| Mr. Mark Paul Wendland |
Chief Executive Officer and Chairman of the Board |
06/02/2026 |
| Mr. Sireesh Appajosyula |
Director and Chief Operating Officer |
31/03/2026 |
| Mr. Gary S. Stetz |
Independent Director |
31/03/2026 |
| Ms. Jill E. Sommers |
Independent Director |
31/03/2026 |
| Mr. William Wiley |
Independent Director |
31/03/2026 |
|
|
|
|
